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ABSTRACT
To address deficiencies in Current Procedural Terminology (CPT) codes that describe many of the clinical
services offered to patients, several physicians in the blood and marrow transplantation and apheresis field
joined with a coalition including the American Society of Hematology, American Society for Blood andMarrow
Transplantation, American Association of Blood Banks, American Society of Clinical Oncology, American
Society for Apheresis, National Marrow Donor Program, and American Red Cross to collaborate in addressing
these deficiencies by designing new CPT codes. The CPT editorial panel approved 18 new or revised codes.
All these codes were given permanent or temporary value by the relative value unit update committee, but not
all values were approved by the Centers for Medicare & Medicaid Services (CMS), in particular, the cell-
processing codes and the unrelated donor search code. Further discussions addressing these concerns are
under way with the CMS. Use of these new codes allows apheresis and transplant centers to charge appro-
priately for these services. This will help transplant center contracts with CPT codes, with payers more
specifically describing services offered to these patients. In turn, this will give better justification for payment.
This may allow certain payments for services to increase and help transplant centers better allocate revenue
from fixed global case rate payments. Details about the individual codes and their approval process are reviewed
in this article.
© 2005 American Society for Blood and Marrow Transplantation
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wNTRODUCTION
For many years, hospitals and physicians provid-
ng blood and marrow transplantation (BMT) and
pheresis services were frustrated and disadvantaged T
B&MTy the lack of adequate procedure codes to describe
nd bill for components of BMT services. For exam-
le, there was only 1 cell-processing code, 86915,
hose descriptor was the removal of T and B cells.
he American Medical Association (AMA) Current
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8rocedural Terminology (CPT) staff recommended
hat all cell processing, including freezing and thawing
tem cells and removing red blood cells and plasma, be
illed under code 86915. This recommendation was
nadequate because the techniques required for any of
hese different steps consume signiﬁcantly different
esources. The Centers for Medicare & Medicaid Ser-
ices (CMS) commonly applies a “2 times” rule when
eﬁning homogenous groups of procedures for pay-
ent purposes; therefore, any individual step (eg,
reezing of stem cells versus removal of red cells) that
as a resource consumption of greater than 2 times its
ounterpart should never be placed in the same pay-
ent group. To achieve appropriate payment, CPT
odes require speciﬁcity, which is often referred to in
he coding system as granularity. The apheresis and
MT issues met these criteria.
In 1992, the Healthcare Financing Administra-
ion, the predecessor to the CMS, implemented the
esource-Based Relative Value Scale (RBRVS) for
ayment of physician professional services. The orig-
nating RBRVS regulation mandated 1 payment per
PT code per patient bill. Payments made under the
BRVS system were arranged into 3 components. All
PT codes were valued for (1) physician services, (2)
alpractice expense, and, if applicable, (3) practice
xpense. Practice expense should pay for the technical
ervices provided for the procedure, including techni-
ian work effort, supplies, building and equipment
osts, and overhead. In 1999, the Health Insurance
ortability and Accountability Act mandated that all
ayments for interstate medical services be billed by
sing common code sets according to the Healthcare
ommon Procedure Coding Systems (HCPCS). Level I
odes were deﬁned as the CPT codes. HCPCS level II
odes are generally used for services that help to facil-
tate purchasing outside products, such as blood prod-
cts or pharmaceuticals, and administering them to
atients. These 2 events furthered concerns of the
MT community about the lack of CPT codes to fully
escribe the services, including the variation in re-
ource consumption.
To address these deﬁciencies, in 2001, several phy-
icians in the BMT and apheresis ﬁeld and the American
ociety of Hematology (ASH) worked collaboratively to
esign new CPT codes for BMT and apheresis services.
coalition was formed to assist in this endeavor, includ-
ng the ASH, American Society for Blood and Marrow
ransplantation, American Association of Blood Banks,
merican Society of Clinical Oncology, American Soci-
ty for Apheresis, National Marrow Donor Program,
nd American Red Cross. Consultation was also per-
ormed with relevant international societies, particularly
he International Society of Cellular Therapeutics. The
bjective of the initiative was to obtain new CPT codes
o meet the needs of the hematopoietic progenitor cell
nd apheresis community. These new codes would be t
72sed to obtain adequate payment by describing and doc-
menting the clinical service associated with BMT and
pheresis. Because cross-subsidization is being discour-
ged by the CMS and other third-party payers, addi-
ional tangential beneﬁts of the initiative included facil-
tating appropriate cost-ﬁnding techniques for these
ervices and using the values associated with these codes
or equitably allocating internal distribution of ﬁxed
ase-rate payments for global BMT services. This article
escribes the actions taken to develop new codes and
heir current status. Some background, however, would
rst be useful.
Proposals for new CPT codes for medical proce-
ures not adequately deﬁned by current CPT codes
re sent to the AMA CPT editorial panel, where they
re considered and voted on (Figure 1). For Medicare
urposes, newly approved CPT codes are sent to
he AMA/Specialty Society Relative Value Scale Up-
ate Committee (RUC). This committee evaluates the
hysician work effort for the procedure in relation to
ll other services on the physician fee schedule and
ssigns the procedure a relative value unit (RVU;
igure 2). The committee also evaluates the direct
ractice expenses (eg, technical staff, supplies, and
quipment) incurred by physicians in performing a
ervice in the outpatient setting. The RUC sends its
ecommendations on both physician work and prac-
Figure 1. The CPT process.ice expenses to the CMS, which may accept, not
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Bccept, partially accept, or reject the recommenda-
ions. As discussed below, for some of the new trans-
lant-related codes, the RUC’s recommendations
ere not accepted by CMS. (Note: The costs incurred
y the hospital for outpatient care are reimbursed
hrough different payment systems; however, these
ayments are still based on the CPT code system.)
PHERESIS CODES: 36511-36516
Historically, apheresis included only generic aphe-
esis codes: a plasma pheresis code and a photophere-
is code. New codes were needed to appropriately bill
xpenses for differing apheresis services because of the
ariable cost of disposables and the higher intensity of
nvolvement of the personnel overseeing and perform-
ng these procedures, particularly those performed on
n emergency basis, such as plasma exchange for
hrombotic thrombocytopenia purpura or leukaphere-
is for newly diagnosed myeloid leukemias with very
Figure 2. The RUC process.
able 1. Comparison of Old Pheresis Codes with New Codes
Old
Code Title RVU
New
Cod
36520 Therapeutic apheresis; plasma
and/or cell exchange
1.74 3651
3651
3651
3651
36521 Therapeutic apheresis; with
extracorporeal affinity
column adsorption and
1.74 3651
3651
plasma reinfusion
B&MTigh leukocyte counts. This is important because the
ime for performing a white blood cell removal or
lasma exchange may be far greater than that for a
latelet exchange or for a red blood cell removal. To
chieve this speciﬁcity, or granularity, therapeutic
pheresis has now been split into 36511 for leuka-
heresis, 36512 for red blood cell exchange, 36513 for
latelet pheresis, 36514 for plasma pheresis, 36515 for
lasma pheresis with extracorporeal immunoabsorp-
ion and plasma reinfusion, and 36516 for plasma
heresis with extracorporeal selected ﬁltration and
lasma reinfusion. The code for photopheresis was
eft unchanged. The Practice Expense Advisory Com-
ittee valued several of the new codes as non–facility-
ased services (36514, 36515, and 36516). Each code
s priced for disposables and nursing care (see Table 1
or the payment schedule). In 2004, the RUC com-
ittee clariﬁed that the procedure’s professional fee
oes not require the physician to perform the proce-
ure, but it does require the physician to examine the
dicates Relative Value Scale.
Title RVU
Apheresis for leukapheresis 1.74
Apheresis for red cell exchange 1.74
Apheresis for platelet pheresis 1.74
Apheresis for plasma pheresis 1.74
Apheresis for plasma pheresis with extracorporaeal
immunoabsorption and plasma reinfusion
1.74
Apheresis for plasma pheresis with extracorporeal 1.74e
1
2
3
4
5
6
selected filtration and plasma reinfusion
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8atient during the procedure, demonstrate active su-
ervision of the procedure, and be available during the
rocedure. The physician should document the exam-
nation and active supervision. Available means that
he physician must be in the hospital or facility, but
ot necessarily in the apheresis suite, during the entire
rocedure. Physicians do not need to bill a profes-
ional fee for these services and should not if they are
ot on the premises and do not document any super-
ision of the procedure. A facility fee can be billed.
valuation for apheresis is billable separately as long
s it is performed on a different day and can be done
s a consult evaluation and management (E/M) code.
he postprocedure follow-up is also billable sepa-
ately as long as it is performed on a different day by
sing standard E/M services. Different physicians
rom the same specialty may bill for inpatient services
n the same day. For example, 1 hematologist may
ollow up acute leukemia patients on the inpatient unit
hile a second hematologist performs the apheresis.
NRELATED DONOR SEARCH AND HEMATOPOIETIC
ROGENITOR CELL ACQUISITION: 38204
The 38204 code covers the medical judgment/
ecision making of the physician supervision of coor-
inators performing the unrelated donor search and
he cognitive work effort involved in evaluating and
electing the clinically appropriate product (Table 2).
he physician assessing a patient for a BMT is often
ot the physician supervising the donor search, be-
ause the donor search requires a detailed knowledge
f HLA antigens. Historically, the clinical services
equired for procuring clinically appropriate unrelated
onor cells were billed either with no CPT code or
ith a generic CPT code, such as 38999 (unlisted
rocedure, hemic or lymphatic system). This code
annot be used for services purchased through the
ational Marrow Donor Program or cord blood
anks, such as DR testing or requesting a simple
onﬁrmatory typing (see Table 2 for payment sched-
le). For the facility component, this code will be
isted as facility based. Although this code was origi-
ally developed to cover the physician’s work effort in
upervising the search process, it could also conceiv-
bly be used for billing the administrative costs asso-
iated with an unrelated donor or cord blood search.
able 2. Donor Search
Old
Code Title RVU
New
Code
one None None 38204
Not recognized by CMS; RUC approved interim value.his code may be used only once per search whether b
74uccessful or unsuccessful, no matter how long the
earch lasted. Essentially, the valuation reﬂects an av-
rage amount of time and effort spent by a physician
n managing a donor search. If a second transplanta-
ion is required from the same donor, this code may
ot be used twice; however, if a second transplantation
s performed from a different donor, whether marrow,
eripheral blood stem cells, or umbilical cord blood,
his code may be used a second time. To bill this code,
he physician must document the cognitive work ef-
ort of reviewing the donor search and donor selec-
ion, as well as the negotiations with the appropriate
ollection center for the service. CMS rejected the
UC’s recommendation and questioned the degree to
hich physicians are typically involved in these ser-
ices. CMS believes that the donor search is already a
overed beneﬁt under the allogeneic infusion CPT
ode (38240) for physician work effort. This code was
n original CPT code; however, CPT never fully
eﬁned the scope of work, and RUC has not resur-
eyed the work effort. Most centers have limited the
cope of work to management of the allogeneic pro-
enitor cell infusion. The physician managing the
onor search is rarely the physician performing the
nfusion, because the inpatient physician usually per-
orms the infusion. ASH has had several discussions
ith CMS about this issue and continues to seek to
ave this decision reversed.
LLOGENEIC AND AUTOLOGOUS PERIPHERAL
EMATOPOIETIC CELL COLLECTION BY APHERESIS:
8205-38206
The original common code for peripheral stem
ell collection (38231) was revised and split into 2
odes. This code was originally published in CPT in
999 as a solitary code for apheresis stem cell col-
ection. The code’s deﬁnition did not specify allo-
eneic or autologous transplantation (Table 3). Ad-
itionally, code 38231 did not effectively clarify
hether charges were global or per diem, and this
reated confusion on how to bill stem cell collection
ervices requiring multiple days of collection. There
re 2 new codes for stem cell collection—38205 for
llogeneic and 38206 for autologous peripheral
lood progenitor (stem) cell collection. The codes
re to be reported only once per day. The physician
Title RVU
nrelated donor search and hematopoietic
progenitor cell acquisition
2.0*Uilling for supervision for these codes may not bill
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CPT Codes for Apheresis and BMT Services
B/M services on that day. However, the precollec-
ion assessment can be billed under a standard E/M
s long as it is not performed on the same day the
ervice is provided. Similarly, the postpheresis fol-
ow-up can also be billed under standard E/M as
ong as it occurs on a different day than that of the
rocedure. As with the apheresis CPT codes, to bill
or a professional fee, the physician does not have to
erform the procedure but must examine the pa-
ient during the procedure and demonstrate active
upervision of the procedure. The physician should
ocument this activity. The physician must remain
n the hospital for the entire procedure and be
eadily available if needed at the bedside. The phy-
ician does not need to be in the apheresis suite for
he entire procedure. There is a per-day physician
harge for both of these codes when multiple col-
ections are required, and this charge may be billed
n multiple days. Please note that the assessment of
n allogeneic donor should be billed as a new pa-
ient charge and not as a consult because there is no
eferring physician for a donor visit. The autolo-
ous pre–stem cell collection may be billed as a
onsult history and physical if the physician per-
orming the apheresis is different from the physi-
ian managing the patient’s cancer, if other require-
ents for consultation are met. This can be within
he same specialty; however, the consult cannot be
erformed on the day of collection. CPT codes
8205 and 38206 are valued and approved by CMS.
nlike the apheresis codes, these codes are only
acility-based codes. This means that the use of
hese codes is limited to hospitals or hospital-based
acilities. Before these services are assessed for non–
acility-based centers, the effect of the new Food
nd Drug Administration (FDA) policies and pro-
eedings under Code of Federal Regulations (CFR)
271 must be evaluated. Facility-related expenses
ay include valuing services such as technician
ime, machine disposables, machine depreciation,
pace utilization, and all costs associated with meet-
ng regulatory components, which is of importance
o exempt cancer centers. Hospitals are reimbursed
n the ambulatory patient classiﬁcation system
ased on Medicare claims data. The ambulatory
atient classiﬁcation system bundles hospital pay-
ents for nursing, technician time, supplies, equip-
able 3. Comparison of Old Stem Cell Collection Codes with New Code
Old
Code Title RVU
38231 Blood-derived peripheral stem cell
harvesting for transplantation,
per collection
1.5ent, and hospital overhead. p
B&MTELL-PROCESSING CODES: 38207-38215
The new cell-processing CPT codes (38207 through
8215) were written to allow granularity for cell pro-
essing because the old code, 86915, could not be
riced uniformly to compensate for all cell-processing
rocedures. In 1999, when CMS approved the new
PT codes for stem cell collection (38231), it also
pproved a reference to 2 new codes, 88240 and
8241, which are for freezing and thawing of aliquots
f cells. These codes were written by the American
enetics Society for the purpose of transferring cells
or cytogenetic testing in different laboratories (Table
). They were never intended to be valued on the
acility side for the processing of a transplantable ther-
peutic product. During the writing of the new CPT
odes for cell processing, consideration had to be
iven to the fact that the CPT editorial panel would
ive new codes only for procedural processes that are
enerally accepted as a standard of care. Codes for
tem cell expansion and vaccine preparation were not
roposed because these technologies are still in the
evelopmental stages and not FDA approved. Cell-
rocessing procedure deﬁnitions were based on the
urpose of the cell processing rather than a link to any
ne manufacturer’s device. The CPT editorial panel
nd the RUC committee agreed that these codes
ould be per-day charges. These codes were deﬁned
nd valued with the perspective that the quality-assur-
nce testing was part of the code.
The RUC committee established temporary RVUs
or all of these codes. The RUC agreed that the physi-
ian RVUs were developed for review of data impor-
ant for all cell-processing decisions; supervision of
he technician performing an individual patient’s cell
rocessing; review and interpretation of quality-assur-
nce procedures for individual patient cells being pro-
essed, including ﬂow cytometry; and preparation of a
eport on an individual product’s adequacy and the
bility of that cellular product to meet expectations for
ransplantation. However, it should be emphasized
hat this physician work effort does not include quality
ssurance for the entire laboratory and that quality
ssurance is not being performed for an individual
atient but for the laboratory processes and proce-
ures. Included in the physician work effort is a prod-
ct speciﬁc report that documents the adequacy of the
ew
ode Title RVU
205 Allogeneic peripheral blood progenitor
cell collection
1.5
206 Autologous peripheral blood
progenitor cell collection
1.5s
N
C
38
38roduct to meet the goals of the transplantation.
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88207: Cryopreservation and Storage—Bone
arrow Peripheral Blood Progenitor Cells
The code 38207 is for the freezing and storing of
ematopoietic and lymphopoietic cells for transplan-
ation. Physician judgment and review issues for this
ode include donor/recipient HLA typing; mismatch-
ng; ABO compatibility; infectious disease serology;
onor/recipient size disparity; red blood cell contam-
nation of the product collected; appropriate quality-
ssurance procedures such as CD34, CD3, and mi-
robiology testing; technician review of the freezer
urves; and report generation to review the adequacy
f the cryopreserved product and its ability to meet
peciﬁcations for the intended transplantation. Facil-
ty fees include technician time, laboratory supplies,
achine depreciation, and space utilization. Mononu-
lear cell processing should be billed separately if it is
erformed before cryopreservation. Cryopreservation
acility charges include all quality-assurance testing
or that individual product. Since January 1, 2004, all
ow cytometry procedures for quality assurance of an
ndividual product are included in this code.
8208 (Transplantation Preparation for
ematopoietic Progenitor Cells, Thawing of a
reviously Cryopreserved Progenitor Cell Harvest
ithout Wash) and 38209 (Transplantation
reparations for Hematopoietic Progenitor Cells,
hawing of a Previously Cryopreserved Progenitor
ell Harvest with Wash)
A separate code for thawing, as opposed to cryo-
reservation, was necessary because not all cryopre-
erved products are actually thawed. This code is in-
ended for the thawing of the harvest from the day of
nfusion. This code is a per-day code like the other
ell-processing codes. The physician work effort here
able 4. Comparison of Old Cell Processing Codes with New Codes
Old
Code Title RVU
New
Code
88240 Cryopreservation, freezing, and
storage of cells, each cell line
—* 38207
88241 Thawing and expansion of
frozen cells, each aliquot
—* 38208
38209
86915 Modification, treatment, and
processing of bone marrow
or blood-derived stem cell
specimens for
transplantation
—* 38210
38211
38212
38213
38214
38215
Not recognized by CMS; RUC approved interim value.s a review of special procedures necessary for the f
76hawing of the product, including needs for washing
he product or addressing concerns about incompati-
le red blood cell contamination. The facility compo-
ent includes all equipment, machine depreciation,
pace utilization, technician time used in the thawing
rocess, and postthaw viability testing. If there is any
ostthaw ﬂow cytometry testing, then it should be
ncluded as a part of the facility and professional com-
onent. Starting in 2004, 38208 is for a thaw without
wash and 38209 is for transplantation preparation of
ematopoietic progenitor cells and thawing and wash-
ng a previously cryopreserved product. Code 38209
as designed for washing thawed cells to remove di-
ethyl sulfoxide. The facility fees should include
echnician time, machinery, supplies, machinery de-
reciation, and prewash and postwash viability testing.
8210: Specific Cell Depletion within a
arvest—T-Cell Depletion
The code 38210 covers the removal of T cells
rom a bone marrow or stem cell harvest to prevent
raft-versus-host disease. The physician work assess-
ent and decision making is assessing the need for
-cell depletion for prevention of graft-versus-host
isease; assessing donor/recipient suitability for a T
ell–depleted transplant, including HLA typing and
onor/recipient size disparity; assessing the quality of
he product coming to the laboratory for T-cell de-
letion; obtaining CD34 and CD3 counts; supervising
he technician processing the hematopoietic progeni-
or cells for T-cell depletion; assessing the efﬁcacy of
he T-cell depletion; and judging the quality of prod-
ct adequacy. Facility fees include the machinery, ma-
hinery depreciation, technician time, space utiliza-
ion, and quality-assurance testing.
If cryopreservation (38207) is to be performed be-
Title RVU
HCPCS
G-Code
opreservation and storage; bone marrow
eripheral blood progenitor cells
0.89 G0265
nsplantation preparation for
ematopoietic progenitor cells; thawing of
previously cryopreserved progenitor cell
arvest without wash
0.56 G0266
wing of a previously cryopreserved
rogenitor cell harvest with wash
0.24 G0266
cific cell depletion within a harvest;
-cell depletion
1.57 G0267
or purging 1.42 G0267
cell removal 0.94 G0267
elet depletion G0267
ma volume depletion 0.81 G0267
l concentration of plasma mononuclear
uffy coat layer
0.94 G0267Cry
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Beparately. If mononuclear cell separation (38215) is
ot usually performed before T-cell depletion, then it
ay also be charged separately. The facility fee should
nclude the test to evaluate the efﬁcacy of T-cell de-
letion and the product viability after T-cell deple-
ion, and these will include preprocessing and post-
rocessing.
8211: Specific Cell Depletion within a
arvest—Tumor Purging
Tumor purging is similar to T-cell depletion and
s used for an autologous product to purge contami-
ating tumor cells. Physician decision making and
ssessment consists of determining the necessity for
umor purging, assessing the quality of the product
eceived in the laboratory for tumor purging, super-
ising technical staff, assessing the efﬁcacy of the pro-
edure, and reviewing the quality of the product to
eet speciﬁcations. The facility fees should include all
he machinery equipment, depreciation, technician
ime, space utilization, and supplies for performing
umor purging. Because cryopreservation is always
erformed in the context of tumor purging for an
utologous transplantation, this should be included in
he charge. Mononuclear cell separation is not always
erformed before tumor purging and should not be
ncluded in the pricing.
8212: Specific Cell Depletion within a
arvest—Red Cell Removal
This CPT code should be used for a fresh alloge-
eic bone marrow harvest with major ABO incompat-
bility for removal of red blood cells in preparation for
ransplantation. Facility fees include technician time,
upplies, machinery, and red cell blood depletion for
major ABO-incompatible marrow harvest. This is
erformed for quality-assurance testing for the efﬁ-
acy of red blood cell removal, as well as for the
iability of progenitor cells after red blood cell re-
oval. Starting in 2004, this CPT code includes ﬂow
ytometry testing for quality assurance.
8213: Specific Cell Depletion within a
arvest—Platelet Depletion
Code 38213 is for a donor undergoing a multiple-
ay progenitor cell harvest who requires a platelet soft
pin to add back platelets as a result of a decrease in
latelet count after the progenitor cell collection.
here has been controversy about whether there are
ny RVUs because there is no explicit quality assur-
nce of this product after it is given back to a donor
ith a low platelet count.
8214: Plasma Volume Depletion
Plasma volume depletion is performed on a fresh
one marrow harvest for plasma removal for the pur- 8
B&MToses of either minor ABO incompatibility or volume
eduction in the circumstance in which the donor is
uch larger than the recipient.
8215: Cell Concentration of Plasma Mononuclear
uffy Coat Layer
Cell concentration of the plasma mononuclear
uffy coat layer is for mononuclear cell separation for
ither major or minor ABO incompatibility from a
resh bone marrow harvest or when a mononuclear
ell separation is necessary for further cell processing,
uch as T-cell depletion or tumor purging. This
hould be billed in the latter circumstance only if is
ot routinely performed for all purging or procedures.
he professional work component includes assessing
he need for mononuclear cell separation; reviewing
he donor/recipient size, ABO blood types, and the
uality of the product reaching the laboratory; ensur-
ng that the product after processing meets the pa-
ient’s speciﬁc needs; and generating a report. Facility
ees include technician time, supplies, machinery, and
iability testing, including ﬂow cytometry.
MS CONCERNS WITH CELL PROCESSING
CMS did not approve the cell-processing codes
8207 to 38215. CMS chose not to value these ser-
ices but chose to create HCPCS level II codes in the
-code section for cell processing (G0265, G0266,
nd G267). The G-codes G0265 and G0266 mirror
odes 88240 and 88241 and have been valued by CMS
or cell processing at approximately $11 for facility
ompensation only. There is no professional fee com-
ensation for any HCPCS level II G-codes. CMS
ttached these codes to the laboratory fee schedule as
result of its belief that cell processing is entirely
utomated. CMS seems not to appreciate the unique
ature of BMT services and why these are different
rom simply sending cells across state lines for routine
aboratory testing. How the FDA’s new policies and
rocedures with CFR 1271 will affect CMS’s thinking
s unknown. Further discussions with CMS are under
ay. Preparation of a patient-speciﬁc cellular product
or transplantation is a novel concept to CMS, espe-
ially in light of 8 codes replacing 1 code. The BMT
ommunity had never participated in this process,
hich is why so many new codes were needed. How-
ver, codes 38207 to 38215 can and should be used
or billing these services to nongovernmental payers.
hese new codes will more accurately describe BMT
ervices to nongovernmental payers. With CMS’s lack
f coverage, the BMT community is not worse off
han it historically was when codes 88240 and 88241
ere valued as facility expenses by CMS at $11 and
lso did not have professional fee compensation. Code
6915 was valued at only $32. G-code G0267 would
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J. L. Gajewski et al.
8e used for CPT code 86915 for a facility charge for
rocedures other new cryopreservation and thawing.
hese codes were presented as facility-based for prac-
ice expense allocation. CMS has no historical data for
hese codes. Cell-processing expenses, if reviewed at
ll, fell under the inpatient diagnosis-related groups
or nonexempt cancer centers or outpatient donor
ills. BMT is an infrequent procedure for Medicare
eneﬁciaries because, until recently, BMT was limited
o patients younger than 45 years of age. This has
mpeded CMS from collecting accurate data about
MT services.
ONOR LYMPHOCYTE INFUSIONS: 38242
Billing donor lymphocyte infusions to treat re-
apse or viral infections after an allogeneic transplan-
ation is problematic. Many institutions used the allo-
eneic transplantation CPT code 38240, but this code
as difﬁcult to justify with the small volume of cells
sed to treat viral infections. For this reason, several
embers of the specialty coalition working on these
odes insisted on creating a new code to clearly deﬁne
his service (Table 5). An additional reason for this
ode was that different physicians often performed the
nitial transplant infusion and the donor lymphocyte
nfusion. The code was clearly deﬁned as a single-day
ervice limited to managing complications with the
onor lymphocyte infusion and the risk associated
ith the infusion. The physician work effort includes
eviewing the donor-recipient identity, approving the
ell dose infused to meet the clinical needs of treating
he recurrent malignancy or infection, obtaining con-
ent from the patient, ordering the premedications,
nfusing the product, and managing any acute toxici-
ies with the infusion. The professional liability risk
ncludes all of the former, plus the risk of long-term
omplications. If the cell-processing laboratory per-
orms the cryropreservation and thawing of the prod-
ct for the infusion, then the cell-processing facility
ervices, including patient-speciﬁc quality assurance,
hould be charged under those codes. In the outpa-
able 5. Comparison of Old Cell Infusion Codes with New Codes
Old
Code Title RVU
38240 Bone marrow or blood-derived
peripheral stem cell
transplantation; allogeneic
2.24
38241 Bone marrow or blood-derived
peripheral stem cell
transplantation; autologous
2.24
/A indicates not applicable.
This code was derived from but did not replace 38240.ient setting, the facility services would include nurs- g
78ng care management. If neither cell processing nor
ryopreservation is necessary, then the facility fee may
lso include the quality-assurance testing of the prod-
ct. This also applies to CPT code 38240 for fresh
nfusions when no cell processing is performed.
ONGOVERNMENTAL PAYERS
For the nongovernmental payer, there is a need to
et rates for these services in the provider’s charge
escription master ﬁle. In the case of all new CPT
odes, decisions about rate setting must be made with-
ut the beneﬁt of market data. It is easier to defend
ates for these services if the rates for these services are
eveloped from a cost of service. One accounting
ethod for achieving appropriate rates based on cost
s the activity-based costing (ABC) method. The focus
f this costing approach is deﬁning the “activities as
he fundamental cost objects” and using “the costs of
hese activities as building blocks for compiling the
osts of other cost objects.” That is, costs are accu-
ulated for each step in the cell-processing process
nd are then collected and applied to speciﬁc new
PT codes separately, as applicable. With this ap-
roach, the cell-processing procedures can be re-
iewed step by step. The activities can be documented,
nd the cost of each activity along the continuum of
rocessing the cells is recorded in a building-block
ashion. Once all activities surrounding a procedure
re deﬁned and documented, other cost drivers—such
s overhead, equipment, and building expenses—can
e further stacked to produce a fully loaded cost per
rocedure. Although this process can be time consum-
ng, it provides excellent justiﬁcation for rates when
here is no established market rate. The role of an
dministrative professional is to challenge the clini-
ian to consider all the costs involved in each step and
o map those steps to the applicable individual CPT
ode. The role of the clinician is to impart the clinical
xpertise about the process so that all costs can be
dentiﬁed and valued. Costs in the case of stem-cell
rocessing range from technician time to liquid nitro-
New
Code Title RVU
N/A
N/A
38242 Donor lymphocyte infusion* 1.71en to quality-control measures, with much more in
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CPT Codes for Apheresis and BMT Services
Between. The results of the ABC method can provide
obust information for rate setting, managed care con-
ract negotiation, and properly supporting and de-
ending payments with government regulators and
ayers. The ABC method is a bottom-up approach to
etermining practice expense, as opposed to the top-
own methodology used by CMS. At M.D. Anderson
ancer Center, the decision was made to price the
ervices these codes describe in relation to the cost of
erforming the service. This would be the most de-
ensible approach to payers and potentially would help
n the equity of internally allocating global ﬁxed pay-
ent case rates. Better accounting for these services
hrough the use of these CPT codes will help BMT
roviders and payers to negotiate fairer case-rate pay-
ent prices. Time/motion studies were used to assess
echnician time, supplies, machine use, machine de-
reciation, space costs, facility malpractice risk, qual-
ty assurance, testing on an individual product, and
nstitutional overhead to develop a cost-based pricing.
he pricing may actually include an amortization of
ood manufacturing practice laboratory construction
osts; however, the amortization must be over 10
ears.
RITICAL CARE CODES: 99291-99292
Although the critical care codes are not new, given
he serious condition of inpatient BMT patients,
trong consideration should be given to using critical
are codes to describe inpatient physician services
ather than standard inpatient E/M codes (99221-
9233). The criteria for critical care service and crit-
cal care can be rendered for patients not in the med-
cal intensive care unit. Critical care is deﬁned as
irect delivery of care by a physician for a critically ill
r critically injured patient when there is a high prob-
bility for imminent or life-threatening deterioration
f 1 or more organ systems. Critical care involves
ighly complex decision making to assess, manipulate,
nd support vital system functions to treat single or
ultiorgan system failure or to prevent further life-
hreatening deterioration of the patient’s condition.
here is an advantage of critical care services because
his is a time-based code. Critical care usually pays
ore than the most complex inpatient E/M codes
Table 6). This code best describes physician services
nvolved in caring for highly unstable BMT inpatients.
UMMARY
Scientists and clinicians may question why all this
dministrative distraction is worthwhile. In a technol-
gy-driven clinical environment such as BMT, lack of
ttention to these coding and payment issues could
eopardize the advancement of medical care. Why? C
B&MTecause the coding and payment systems have not
ept pace with the clinical technology. Traditionally,
MT providers have been disadvantaged ﬁnancially
y their lack of participation in the payment and
ate-setting process. Strenuous efforts are needed to
irect the regulatory process forward and to educate
egulators on emerging clinical advances. Designing a
evenue structure to bill these new codes does require
signiﬁcant investment of clinician time. Case-rate
ayment models will not insulate providers from these
ime requirements. Cost shifting is hard to defend.
ancer care pharmacy charges are being seriously
xamined under public scrutiny. Pharmacy charges are
ften 50% of a BMT patient’s total bill. Pressures on
ayments from government sources and private payers
ill force clinicians to partner with other professionals
o fully describe their services to ensure adequate
ayments, including global case-rate payments.
rends in health care ﬁnancing indicate that the BMT
ommunity will face heightened scrutiny of clinical
aboratory and pharmacy pricing. Traditionally, pay-
ents made for those services cross subsidized re-
ource-intense, technologically advanced BMT ser-
ices such as cell processing, apheresis, and donor
earching. Appropriate descriptions of services cou-
led with appropriate cost-ﬁnding techniques will be
ritical because cost shifting cannot continue to pro-
ide adequate compensation for these costs. This is
articularly dramatic in the context of the need for
MT providers to build cell-processing laboratories
hat meet good manufacturing practice standards for
he new products and technologies being developed in
he ﬁeld. The new federal regulations for cell process-
ng (CFR 1271) require greater technologist time for
roduct preparation, greater physician supervision,
nd, for many, facility renovation or construction.
nly by speciﬁcally billing for cell-processing services
ill institutions recoup these new costs. Pharmacy and
outine laboratory services are under greater security.
inally, with ﬁxed compensation, whether diagnosis-
elated groups or case rates, the distribution of the
ase rate within a facility is often dependent on the
ork effort of the components of the bill. These new
able 6. Comparison of Critical Care Codes with Inpatient Follow-Up
odes
Code Title RVU
99291 Critical care E/M; first 30-74 min 5.44*
99292 Critical care E/M; each additional 30 min 2.72*
99231 Subsequent hospital care, per day, E/M,
stable, 15 min
0.89
99232 Subsequent hospital care, per day, E/M,
minor complications, 25 min
1.47
99233 Subsequent hospital care, per day, E/M,
major complications, 35 min
2.09
Total RVU.PT codes help clarify these efforts within institu-
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8ions for better revenue allocation and help reduce risk
f fraud and abuse by clear deﬁnitions, which were
acking in the old codes.
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